Smooth muscle relaxants v placebo for irritable bowel syndrome (trial duration 3 d to 24 wks)*
| Unweighted event rates | ||||||
|---|---|---|---|---|---|---|
| Improvements | Drug | Number of studies | Drug | Placebo | RBI (95% CI) | NNT (CI) |
| *Abbreviations defined in glossary; RBI, NNT, and CI calculated from data in article. | ||||||
| Global | All | 22 | 56% | 38% | 49% (37 to 61) | 6 (5 to 8) |
| Mebeverine | 4 | 52% | 37% | 47% (9 to 84) | 4 (6 to 31) | |
| Cimetropium | 5 | 60% | 40% | 63% (29 to 92) | 4 (3 to 9) | |
| Trimebutine | 4 | 53% | 24% | 98% (63 to 117) | 5 (4 to 7) | |
| Otilonium | 3 | 97% | 34% | 60% (33 to 87) | 5 (4 to 9) | |
| Hyoscine | 3 | 53% | 42% | 26% (7 to 124) | 10 (2 to 32) | |
| Pain | All | 11 | 53% | 41% | 30% (16 to 45) | 9 (6 to 16) |
| Otilium | 3 | 47% | 29% | 62% (30 to 96) | 7 (4 to 12) | |
| Cimetropium | 1 | 87% | 27% | 198% (81 to 253) | 2 (2 to 5) | |
| Distention | All | 6 | 44% | 35% | 26% (6 to 46) | 12 (7 to 46) |